2011
DOI: 10.2741/e334
|View full text |Cite
|
Sign up to set email alerts
|

The effect of pharmacological treatment on ADMA in patients with heart failure

Abstract: Asymmetric dimethylarginine (ADMA) plays a crucial role in the arginine-nitric oxide (NO) pathway. NO plays an important role in controlling vascular tone and regulates the contractile properties of cardiac myocytes. The purpose of this study was to investigate the effect of pharmacological treatment on asymmetrical dimethylarginine (ADMA) plasma levels in patients with acute congestive heart failure (HF). Patients with symptomatic acute congestive HF (NYHA Class III-IV) and impaired left ventricular (LV) func… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2011
2011
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 20 publications
(22 reference statements)
0
8
0
Order By: Relevance
“…This proinflammatory effect, together with the indirect effects of SDMA on NO synthesis, and the relationship of SDMA to renal function are thought to be possible mechanisms by which SDMA and CVD may be linked (34). Although no evidence exists as yet that SDMA inhibits NO synthase, it may interfere with arginine transport into the cells and, therefore, NO production could be reduced indirectly as already shown by others (35)(36)(37). The high SDMA concentrations in renal patients with CAD could indicate such an increase in vascular tone (38,39).…”
Section: Discussionmentioning
confidence: 87%
“…This proinflammatory effect, together with the indirect effects of SDMA on NO synthesis, and the relationship of SDMA to renal function are thought to be possible mechanisms by which SDMA and CVD may be linked (34). Although no evidence exists as yet that SDMA inhibits NO synthase, it may interfere with arginine transport into the cells and, therefore, NO production could be reduced indirectly as already shown by others (35)(36)(37). The high SDMA concentrations in renal patients with CAD could indicate such an increase in vascular tone (38,39).…”
Section: Discussionmentioning
confidence: 87%
“…Urinary ADMA and creatinine levels were determined as previously reported 41‐43 . The HPLC apparatus consisted of a Jasco PU‐2080 chromatographic pump and a Jasco MD‐2010 Plus absorbance detector.…”
Section: Methodsmentioning
confidence: 99%
“…There is not only evidence that these molecules modulate NO synthesis in vivo , but also that this pathway has a primary role in the pathogenesis of disease. In addition, a degree of tissue/cell specificity of the enzymes controlling methylarginine levels, along with potential for playing a key homeostatic role in NO synthesis, makes this pathway an attractive target for therapeutic intervention [22,23]. There have been a series of in vitro , in vivo , and clinical investigations designed to characterize the pathological role of the endogenous methylarginines in human health and disease (Table 1).…”
Section: Adma In Oxidative Stress Inflammation and Cardiovascular DImentioning
confidence: 99%
“…ADMA has been suggested as a novel independent risk factor for endothelial dysfunction and coronary heart disease. Increased plasma levels of ADMA have been documented in several conditions that are characterized by endothelial dysfunction, including hypertension, hypercholesterolemia, hyperglycemia, renal failure and tobacco exposure (Figure 2) [22,29,36]. …”
Section: Adma In Oxidative Stress Inflammation and Cardiovascular DImentioning
confidence: 99%